Sign In
Buy BEAM
$25.52
-0.97 (-3.66%)
At Close: Jul 31, 2026
All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
07:00am, Friday, 06'th Dec 2024
CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appo
Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report?
12:36pm, Thursday, 05'th Dec 2024
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
07:00am, Wednesday, 04'th Dec 2024
CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appo
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
04:01pm, Tuesday, 12'th Nov 2024
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Joh
Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch
02:25pm, Thursday, 07'th Nov 2024
Beam Therapeutics Inc. will present additional data from phase 1/2 BEACON study, using BEAM-101 for the treatment of patients with SCD at the upcoming ASH Annual Meeting on December 7th - 10th of 2024
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
12:41pm, Wednesday, 06'th Nov 2024
BEAM's third-quarter 2024 earnings and revenues miss estimates. The company remains focused on pipeline development.
Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript
11:54am, Tuesday, 05'th Nov 2024
Beam Therapeutics Inc (NASDAQ:BEAM ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Holly Manning - Vice President of Investor Relations & External Communications Jo
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates
08:42am, Tuesday, 05'th Nov 2024
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.22 per share a year ago.
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
06:30am, Tuesday, 05'th Nov 2024
Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting
CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the comp
Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?
12:36pm, Thursday, 05'th Sep 2024
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?
3 Gene Editing Stocks with Potential to Transform Medicine
10:19am, Friday, 09'th Aug 2024
Gene editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. It could help treat the 7,000 diseases caused by genetic disord
Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss
11:52am, Wednesday, 07'th Aug 2024
Beam Therapeutics (BEAM) reports mixed second-quarter results. The company remains focused on pipeline development.
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
08:46am, Tuesday, 06'th Aug 2024
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.08 per share a year ago.
